By Business/Source
Currency:USD
2020/FY
Stock NameRevenueRatio
Research and development Company’s novel orally administered antiviral influenza candidate2.01M100.00%
By Country/Region
Currency:USD
2020/FY
Stock NameRevenueRatio
United States2.01M100.00%